iCad (Nasdaq:ICAD) announced today that it amended its development and commercialization agreement with Google Health.
The amendment enables iCad to integrate Google’s AI technology with its ProFound Breast Health Suite for 2D mammography. It intends to integrate the AI capabilities upon regulatory approval as an independent reader for breast cancer screening.
ProFound Detection, a high-performance deep learning cancer detection solution, improves detection and workflow efficiency in mammography. It has availability for both 2D and 3D mammography to rapidly and accurately analyze each image. The suite then alerts radiologists of suspicious areas that may warrant a closer look.
“By leveraging the remarkable capabilities of ProFound Detection, iCAD seeks to provide a viable alternative to the current double-reading workflow,” said Dana Brown, president and CEO of iCAD. “Combining Google’s [AI] technology with our leading-edge ProFound Breast Health Suite of AI solutions will enhance our technology and expand access to the technology to millions of women and providers worldwide. Furthermore, Google has already been exploring the use of its technology as an independent reader, with extremely promising results.”
iCad previously signed a strategic development and commercialization agreement with Google Health in November 2022. Through this, they aimed to integrate Google’s AI into iCad’s breast imaging solutions, including ProFound Detection.
The company said an independent study of six radiologists found that Google’s mammography AI system outperformed all human readers.
“Technology can and should play a fundamental role in democratizing access to high-quality healthcare. But one company can’t make this a reality alone,” said Greg Corrado, head of health AI, Google. “iCad is a proven leader in the breast cancer domain, and through this collaboration we hope to not only alleviate the increasing burdens on radiologists worldwide, but also reduce disparities in healthcare across the globe.”
